+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 100Years
All Genders
ID06402968

Study Comparing IV Clevidipine With Other IV Antihypertensive Treatments in Adults With Acute Intracerebral Hemorrhage and High Blood Pressure

Led by Zeenat Qureshi Stroke Institute · Updated on 2026-10-30

1018

Participants Needed

21

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are comparing how quickly people with high blood pressure and intracerebral hemorrhage ICH can reach a stable target systolic blood pressure SBP within 60 minutes using two different intravenous treatments. The study focuses on patients with acute stroke symptoms and elevated SBP between 150 and 220 mmHg, aiming to evaluate the effectiveness of clevidipine versus other standard IV antihypertensive regimens. This research is sponsored by the Zeenat Qureshi Stroke Institute and involves adults aged 18 to 100 years. Participants receive either IV clevidipine or an alternate IV antihypertensive medication depending on the hospital type. Clevidipine dosing starts at 1-2 mghour and is adjusted frequently to reach the blood pressure goal, with dose increases slowing as the target is approached. Doses typically range from 4-6 mghour, with a maximum infusion volume limit to avoid lipid overload. The alternate regimen often involves IV nicardipine, starting at 5 mghour and adjusted as needed per FDA guidelines. Treatment initiation occurs within 12 hours of neurological symptom onset. During the study, participants undergo blood pressure monitoring every 15 minutes to assess stability and response to treatment. Eligibility includes clinical stroke signs and confirmed brain hematoma on CT scan, with follow-up visits planned at 90 and 180 days after enrollment. Informed consent is required, and patients undergoing surgical or drainage interventions under guideline timing are included unless surgery is performed within 6 hours of treatment start. Safety and treatment effects are carefully tracked throughout the study period ending in 2028.

CONDITIONS

Brief Title

Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here